1. Clinical Overview
Denosumab is a fully human monoclonal antibody (IgG2) that binds with high affinity and specificity to RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand), a key mediator of osteoclast formation, function, and survival. By inhibiting RANKL, denosumab prevents osteoclast-mediated bone resorption, leading to increased bone mineral density (BMD) and reduced fracture risk. The 60mg dose is specifically indicated for the treatment of postmenopausal osteoporosis in women at high risk for fracture.
| Onset | Duration | Bioavailability |
|---|---|---|
| Rapid suppression of bone resorption markers (e.g., serum CTX) occurs within 24 hours, with maximal suppression (≥80%) observed within 3 days of administration. | The pharmacodynamic effect on bone resorption markers is sustained for approximately 6 months, necessitating subcutaneous administration every 6 months. Bone mineral density gains are maintained with continued dosing. | Absolute bioavailability following a single 60mg subcutaneous injection is approximately 62%. |
2. Mechanism of Action
Denosumab is a human monoclonal antibody that mimics the action of endogenous osteoprotegerin (OPG). It binds with high affinity to RANKL, a transmembrane or soluble protein essential for the formation, function, and survival of osteoclasts. By binding RANKL, denosumab prevents its interaction with the RANK receptor on osteoclast precursors and mature osteoclasts. This inhibition disrupts osteoclastogenesis, decreases osteoclast activity, and reduces osteoclast survival, leading to a profound decrease in bone resorption.
3. Indications & Uses
- Treatment of postmenopausal women with osteoporosis at high risk for fracture (defined as a history of osteoporotic fracture, or multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy).
4. Dosage & Administration
Adult Dosage: 60 mg administered as a single subcutaneous injection once every 6 months.
Administration: Administer by subcutaneous injection in the upper arm, upper thigh, or abdomen. Allow the prefilled syringe to reach room temperature (15-25°C) for 15-30 minutes prior to injection. Do not shake. Inspect for particulate matter and discoloration. Inject slowly. Proper aseptic technique is mandatory. Must be administered by a healthcare professional. Patient must receive adequate calcium and vitamin D supplementation.
5. Side Effects
Common side effects may include:
- Arthralgia (joint pain)
- Pain in extremity
- Hypercholesterolemia
- Musculoskeletal pain
- Cystitis
- Rash
- Pruritus
- Injection site reactions (erythema, pain)
6. Drug Interactions
| Drug | Effect | Severity |
|---|---|---|
| Calcium/Vitamin D Supplements | Concomitant use is REQUIRED to prevent hypocalcemia. Not an adverse interaction. | Essential Coadministration |
| Loop Diuretics (e.g., Furosemide) | May exacerbate urinary calcium excretion, increasing risk of hypocalcemia. Monitor serum calcium closely. | Major |
| Aminoglycosides | May potentiate hypocalcemic effect. Use with caution and monitor calcium. | Moderate |
| Bisphosphonates (e.g., Alendronate, Zoledronic acid) | Concurrent use not recommended. No additive benefit and may increase risk of ONJ and atypical fractures. | Major |
| Immunosuppressants (e.g., TNF inhibitors, corticosteroids) | May increase risk of serious infections. Clinical monitoring advised. | Moderate |
7. Patient Counselling
- DO take calcium (≥1000 mg/day) and vitamin D (≥400-800 IU/day) supplements as prescribed.
- DO inform all your healthcare providers (especially dentists and surgeons) that you are on Denosumab before any invasive procedure.
- DO report any new thigh, hip, or groin pain, which could signal an atypical femoral fracture.
- DO maintain good oral hygiene and have regular dental check-ups.
- DONT stop taking your calcium and vitamin D supplements.
- DONT miss your 6-monthly injection schedule. Mark it on your calendar.
- DONT take any other osteoporosis medication (like bisphosphonates) unless specifically advised by your doctor.
8. Toxicology & Storage
Overdose: No cases of overdose reported in clinical trials. Theoretical concerns include exacerbation of pharmacodynamic effects: severe, symptomatic hypocalcemia, hypophosphatemia, and immunosuppression leading to serious infections.
Storage: Store in a refrigerator at 2°C to 8°C. Do not freeze. Keep the prefilled syringe in the original outer carton to protect from light. Do not shake. If needed, can be kept at room temperature (up to 25°C) in the original carton for a single period of up to 30 days. Once at room temperature, do not return to the refrigerator. Discard if left at room temperature for more than 30 days. Keep out of reach of children.